H
Hankang Capital
Shanghai, Shanghai
Overview
Hankang Capital, established in 2010, is a corporate venture capital firm of Zhongjianxin Group headquartered in Shanghai, China . The firm focuses on investments in sectors like biomedicine, medical equipment, diagnostic reagents, medical services, and other major health fields .
Year Founded
2010
Portfolio Companies
15
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Vivacta Biotechnology (Shanghai) Co., Ltd. | Apr 2026 | Series A | Co-investor |
| Pinnacle Medicines | Mar 2026 | Series B | Co-investor |
| Shanghai Leadingtac Pharmaceutical Co., Ltd. | Dec 2025 | Series B | Lead |
| Phrontline Biopharma | Nov 2025 | pre_series_a_plus | Co-investor |
| AusperBio | Sep 2025 | Series B Extension | Co-investor |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
